Terms: = Lung cancer AND SETD2, ENSG00000181555, 29072 AND Treatment
19 results:
1. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
2. Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.
Zhang L; Wang Y; Wang L; Wang M; Li S; He J; Ji J; Li K; Cao L
J Mol Med (Berl); 2024 Jan; 102(1):69-79. PubMed ID: 37978056
[TBL] [Abstract] [Full Text] [Related]
3. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
Nagasaka M; Zhang SS; Baca Y; Xiu J; Nieva J; Vanderwalde A; Swensen JJ; Spetzler D; Korn WM; Raez LE; Liu SV; Ou SI
BMC Cancer; 2023 Oct; 23(1):1000. PubMed ID: 37853341
[TBL] [Abstract] [Full Text] [Related]
4. METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma.
Shi K; Sa R; Dou L; Wu Y; Dong Z; Fu X; Yu H
Clin Epigenetics; 2023 Sep; 15(1):153. PubMed ID: 37742030
[TBL] [Abstract] [Full Text] [Related]
5. setd2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
[TBL] [Abstract] [Full Text] [Related]
6. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract] [Full Text] [Related]
7. Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis.
Tian H; Wang Y; Yang Z; Chen P; Xu J; Tian Y; Fan T; Xiao C; Bai G; Li L; Zheng B; Li C; He J
Cancer Gene Ther; 2023 Mar; 30(3):507-520. PubMed ID: 36653483
[TBL] [Abstract] [Full Text] [Related]
8. Genomic landscape of pleural and peritoneal mesothelioma tumours.
Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
[TBL] [Abstract] [Full Text] [Related]
9. A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
Nguyen TT; Lee HS; Burt BM; Amos CI; Cheng C
Br J Cancer; 2022 Nov; 127(9):1691-1700. PubMed ID: 35999269
[TBL] [Abstract] [Full Text] [Related]
10. Identifying metabolic reprogramming phenotypes with glycolysis-lipid metabolism discoordination and intercellular communication for lung adenocarcinoma metastasis.
Li X; Tang L; Deng J; Qi X; Zhang J; Qi H; Li M; Liu Y; Zhao W; Gu Y; Qi L; Li X
Commun Biol; 2022 Mar; 5(1):198. PubMed ID: 35301413
[TBL] [Abstract] [Full Text] [Related]
11. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
12. Genetic Determinants of EGFR-Driven lung cancer Growth and Therapeutic Response
Foggetti G; Li C; Cai H; Hellyer JA; Lin WY; Ayeni D; Hastings K; Choi J; Wurtz A; Andrejka L; Maghini DG; Rashleigh N; Levy S; Homer R; Gettinger SN; Diehn M; Wakelee HA; Petrov DA; Winslow MM; Politi K
Cancer Discov; 2021 Jul; 11(7):1736-1753. PubMed ID: 33707235
[TBL] [Abstract] [Full Text] [Related]
13. Histone methyltransferase setd2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
[TBL] [Abstract] [Full Text] [Related]
14. Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.
Taghizadeh H; Zöchbauer-Müller S; Mader RM; Müllauer L; Klikovits T; Bachleitner-Hofmann T; Hoda MA; Prager GW
Thorac Cancer; 2020 Jul; 11(7):1979-1988. PubMed ID: 32438515
[TBL] [Abstract] [Full Text] [Related]
15. Novel molecular targets for the treatment of lung cancer.
Rosell R; Karachaliou N; Arrieta O
Curr Opin Oncol; 2020 Jan; 32(1):37-43. PubMed ID: 31599770
[TBL] [Abstract] [Full Text] [Related]
16. Acquired setd2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.
Kim IK; McCutcheon JN; Rao G; Liu SV; Pommier Y; Skrzypski M; Zhang YW; Giaccone G
Oncogene; 2019 Jan; 38(2):180-193. PubMed ID: 30093630
[TBL] [Abstract] [Full Text] [Related]
17. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract] [Full Text] [Related]
18. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, setd2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract] [Full Text] [Related]
19. Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin.
Wei EY; Chen YB; Hsieh JJ
BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26494726
[TBL] [Abstract] [Full Text] [Related]
